Navigating Biological Barriers: Solid Lipid Nanoparticles in Targeted Drug Delivery

Solid Lipid Nanoparticles (SLNs) represent a significant breakthrough in contemporary nanotechnology, providing a novel approach to enhance medication absorption and overcome biological barriers, particularly the blood-brain barrier (BBB) [1]. These colloidal systems offer a versatile platform for the delivery of diverse therapeutic molecules, including small drugs, peptides, and proteins [1], [2]. Introduced as an alternative to traditional emulsions, liposomes, and polymeric nanoparticles, SLNs offer unique properties such as small size, large surface area, and high drug loading [21].

By combining the advantages of lipid emulsions and polymeric nanoparticles, SLNs mitigate drawbacks like toxicity and poor stability [3], [12]. Their solid lipid core provides a protective environment for encapsulated payloads, shielding them from chemical and enzymatic degradation [3], [4]. As nanotechnology-based drug delivery systems (nanoDDS), SLNs facilitate the overcoming of physiological barriers that otherwise hinder drug delivery to tumors and other diseased tissues [6]. Their adaptability to various administration routes—including oral, parenteral, dermal, and intranasal—makes them a cornerstone of next-generation targeted therapy [7], [12].

TYPES OF BIOLOGICAL BARRIERS

The Blood-Brain Barrier (BBB)

The Blood-Brain Barrier (BBB) is the most challenging architectural complex in brain drug delivery [18]. It is composed of a monolayer of tightly interconnected endothelial capillary cells, supported by astrocyte end-feet and pericytes [3], [8]. The primary function of the BBB is to facilitate the selective entry of nutrients while preventing the passage of toxins and foreign substances into the brain parenchyma [3], [21]. Tight junctions between these endothelial cells result in high electrical resistance and low permeability, creating a formidable barrier for most drugs [4], [8].

Transport across the BBB is highly restricted; only small, highly lipophilic molecules can typically infiltrate by simple passive diffusion [3], [8]. Furthermore, the BBB functions as a metabolic barrier, expressing enzymes that can deactivate therapeutic agents [4], [20]. Active efflux transporters, such as P-glycoprotein, further limit the accumulation of drugs in the central nervous system (CNS) [4]. SLNs are uniquely positioned to navigate these barriers due to their lipid nature, which facilitates transition across the BBB through passive diffusion or specialized endocytotic pathways [6], [17].

GASTROINTESTINAL AND INTESTINAL BARRIERS

MUCOSAL AND RESPIRATORY PATHWAYS

The nasal mucosa is highly vascularized but protected by a mucus layer that can clear nanoparticles [3]. However, the nasal route provides a direct nose-to-brain pathway, allowing drugs to bypass the BBB by diffusing from lipid nanoparticles through the olfactory bulb into the brain [7]. This bypass is crucial for drugs rapidly cleared by hepatic metabolism [7]. Intranasally administered SLNs have been shown to be more effective in crossing the BBB than other formulations [6]. In the respiratory tract, SLNs designed for pulmonary delivery can achieve deep lung deposition and provide prolonged drug release, which is advantageous for treating airway diseases like lung cancer [12], [15].

DERMAL AND OCULAR BARRIERS

The skin's primary function is to act as a protective barrier, with the stratum corneum being the most important layer against the penetration of xenobiotics [16]. SLNs can form a thin, occlusive lipid film over the skin, providing hydration and fluidizing skin lipids to enhance the penetration of active substances [6], [16]. Similarly, the eye possesses unique anatomical barriers like the corneal epithelium [13]. SLN formulations have been shown to improve corneal permeation and increase the bioavailability of therapeutic moieties for treating ocular disorders like glaucoma [12], [25].

CHARACTERISTICS AND PHYSICOCHEMICAL PROPERTIES OF SLNS

COMPOSITION AND STRUCTURE

SLNs are characterized by a solid lipid core at both room and physiological temperatures, generally melting above 40°C [4], [16]. The lipid core is typically composed of biodegradable lipids such as triglycerides, fatty acids, steroids, or waxes [8], [20]. This lipid matrix is stabilized by surfactants or emulsifiers, such as polysorbates or lecithins, which surround the core to lower interfacial tension and stabilize the dispersion [6], [16]. The choice of lipid and surfactant significantly influences the drug-loading capacity and release kinetics of the SLNs [12], [24].

PARTICLE SIZE AND MORPHOLOGY

SLNs are submicron colloidal carriers, with average diameters typically ranging from 10 to 1000 nm [7], [8]. For many biomedical applications, a size range between 50 and 200 nm is preferred to ensure optimal cellular uptake and to exploit the EPR effect in tumors [6], [14]. Morphologically, SLNs commonly exhibit a spherical shape [8]. The nanometric size provides a massive surface area, which enhances the rate of drug dissolution and facilitates interaction with biological membranes [7], [21].

SURFACE CHARGE AND STABILITY

The surface charge of SLNs, measured as zeta potential, is a critical predictor of their long-term physical stability [12]. High absolute zeta potential values prevent aggregation through electrostatic repulsion [12]. The surface charge can be modulated by selecting specific surfactants or by functionalizing the surface with charged ligands [12], [15]. Stability is also influenced by the crystalline nature of the lipid core, which can be assessed using techniques like differential scanning calorimetry (DSC) or X-ray diffractometry [12].

MECHANISMS OF TARGETING

PASSIVE TARGETING AND THE EPR EFFECT

SLNs can achieve site-specific delivery through passive mechanisms, most notably the Enhanced Permeability and Retention (EPR) effect. In solid tumors, the vasculature is often "leaky," with wide gaps between endothelial cells [6], [14]. SLNs, due to their nanometric size, can pass through these gaps and accumulate preferentially in the tumor microenvironment [6], [10]. This passive accumulation improves the therapeutic index of anticancer drugs while reducing systemic side effects [17].

ACTIVE TARGETING AND SURFACE ENGINEERING

To enhance specificity, the surface of SLNs can be engineered with targeting moieties that bind to specific receptors [3]. For BBB targeting, functionalization with ligands such as Transferrin (Tf), Lactoferrin (Lf), or RVG29 peptide has been shown to improve brain distribution [20]. Specific molecular recognition can also be achieved via integrin receptors or by targeting endogenous receptors on brain endothelial cells [5], [15]. Furthermore, modification with polyethylene glycol (PEGylation) helps the nanoparticles escape immune recognition, enhancing their biological half-life [12], [15].

CELLULAR INTERNALIZATION PATHWAYS

SLNs are internalized through various endocytotic pathways, including receptor-mediated endocytosis, adsorptive-mediated transcytosis, and lipid raft-mediated endocytosis [5], [8]. Receptor-targeted surface engineering enables efficient penetration through specific adhesion mechanisms [5]. In the CNS, internalization is thought to be facilitated by endothelial cells via pinocytosis [17]. Furthermore, SLNs can bypass multidrug resistance pathways by modulating efflux transporters like P-glycoprotein [17], [21].

CLINICAL AND THERAPEUTIC APPLICATIONS

NEURODEGENERATIVE DISEASES AND CNS TARGETING

The ability of SLNs to cross the BBB makes them promising candidates for treating Alzheimer's disease, Parkinson's disease, and brain tumors [1], [4], [20]. Specific drugs delivered to the brain via SLNs include donepezil, curcumin, and andrographolide [4], [20]. Erythropoietin-loaded SLNs have shown promising results for improving memory deficits in Alzheimer's models [15]. Intranasally administered SLNs are particularly effective for direct brain targeting, bypassing the BBB via the olfactory bulb [6], [7].

ONCOLOGY AND CANCER TREATMENT

SLNs have been extensively explored for the delivery of various anti-cancer drugs, including doxorubicin, methotrexate, and docetaxel [4], [6], [22]. They address the formulation challenges of tyrosine kinase inhibitors, enhancing their cytotoxic effects and bioavailability [9]. Specific applications include breast, lung, and liver cancer, where SLNs improve cellular uptake and overcome multidrug resistance [17]. For lung cancer, erlotinib-loaded SLNs have been proposed for pulmonary delivery [15].

ORAL DELIVERY AND METABOLIC DISORDERS

SLNs are used to enhance the oral bioavailability of drugs with poor intestinal permeability, such as peptides and proteins like insulin [12], [15]. They protect labile drugs from enzymatic degradation in the GI tract [21]. Insulin-loaded SLNs have shown hypoglycemic effects in diabetic rats [15]. Furthermore, SLNs offer a novel strategy for targeted delivery in metabolic disorders like obesity by providing sustained release and overcoming biological barriers [19], [26].

CONCLUSION

Solid Lipid Nanoparticles represent a robust and versatile technology for navigating the complex biological barriers of the human body. By leveraging their lipid composition, nanometric size, and the potential for surface functionalization, SLNs can effectively overcome the Blood-Brain Barrier, gastrointestinal hurdles, and mucosal defenses. They offer a unique combination of biocompatibility, controlled drug release, and enhanced stability, making them superior to many traditional delivery systems. As research continues to refine targeting strategies and improve drug-loading efficiency, SLNs are poised to play a central role in the future of precision medicine and the treatment of previously intractable diseases.

REFERENCES

1. Mohd Yasira Udai Vir Singh Sarac, Iti Somb, Praveen Gaurb, Monika Singh and Ameeduzzafar. Nose to Brain Drug Delivery: A Novel Approach Through Solid Lipid Nanoparticles. Current Nanomedicine, 2016, Vol. 6(2):1-21
2. Aggarwal K, Joshi S, Jindal P, Kurmi BD. Solid Lipid Nanoparticles: An Innovative Drug Delivery System for Enhanced Bioavailability and Targeted Therapy. AAPS PharmSciTech. 2025 Jul;26(6):186.
3. Sowmya C. Solid lipid nanopartilces: modern progress in nose-to-brain transduction. Int J Appl Pharm. 2023 Jul;15(4):20-6.
4. Gugleva V, Andonova V. Drug delivery to the brain – lipid nanoparticles-based approach. Pharmacia. 2023 Feb;70(1):113-20.
5. Kang M, Hwang W, Yang J, Kim S, Jeon S, Noh M, Lee J, Lee JB, Kim Y, Kim JW. Cell-Penetrating Peptide-engineered Solid Lipid Nanoparticles for Enhanced Endocytotic Internalization and Transdermal Penetration. ACS Appl Nano Mater. 2025 Sep;8(40): 19192–19201.
6. German-Cortés J, Vilar-Hernández M, Rafael D, Abasolo I, da S. Andrade FR. Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment. Pharmaceutics. 2023 Mar;15(3):831.
7. Pawar AK, Hatmode LG, Khandelwal HR, Gurumukhi VC, Chalikwar SS. Solid lipid nanoparticles: Influence of composition, fabrication methods and problems, in vitro drug release and intranasal administration provide to access olfactory bulb pathway for SLNs. GSC Biol Pharm Sci. 2021 Feb;14(2):126-42.
8. Iqbal I, Saqib F, Mubarak Z, Latif MF, Wahid M, Nasir B, Shahzad H, Sharifi-Rad J, Mubarak MS. Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges. Eur J Med Res. 2024 Jun;29(1):313.
9. Satapathy S, Patro CS. Solid Lipid Nanoparticles for Efficient Oral Delivery of Tyrosine Kinase Inhibitors: A Nano Targeted Cancer Drug Delivery. Adv Pharm Bull. 2021 Jul: 298–308.
10. Bayón-Cordero L, Alkorta I, Arana L. Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs. Nanomaterials. 2019 Mar;9(3):474.
11. Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MHA, Silva AM, Souto EB. Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery. J Drug Deliv. 2012:1-10
12. Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021 Apr;9:580118.
13. Mehrdadi S. Solid Lipid Nanoparticles: a promising drug delivery system and their potential for peptide and protein therapeutics. IntechOpen. 2024 May.
14. Basu A, Namporn T, Ruenraroengsak P. Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma. Pharmaceutics. 2023 May;15(6):1611.
15. Rao MR, Sonawane A, Sapate S, Abhang K. Exploring Recent Advances in Nanotherapeutics. J Drug Deliv Ther. 2020 Oct;10(5-S):273-80.
16. Souto EB, Fangueiro JF, Fernandes AR, Cano A, Sanchez-Lopez E, Garcia ML, Severino P, Paganelli MO, Chaud MV, Silva AM. Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery. Heliyon. 2022 Feb;8(2):e08938. 
17. Sivadasan D, Mahendran J, Ranganathan HP, Karuppaiah A, Rahman H. Solid Lipid Nanoparticles: Applications and Prospects in Cancer Treatment. Int J Mol Sci. 2023 Mar;24(7):61-99.
18. Amiri M, Jafari S, Kurd M, Mohamadpour H, Khayati M, Ghobadinezhad F, Tavallaei O, Derakhshankhah H, Sadegh Malvajerd S, Izadi Z. Engineered Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as New Generations of Blood-Brain Barrier Transmitters. ACS Chem Neurosci. 2021 Dec;12(24):4475-90. 
19. Ili? T, ?okovi? JB, Nikoli? I, Mitrovi? JR, Panteli? I, Savi? SD, Savi? MM. Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation. Pharmaceutics. 2023 Jan;15(2):443.
20. Vazzana M, Macedo AS, Santini A, Faggio C, Souto EB. Novel Neuroprotective Formulations Based on St. John’s Wort Extract. J Field Robotics. 2014 Apr;3(4):3-17.
21. Agrawal P, Tatode AA, Umekar MJ. Solid Lipid Nanoparticle for the Delivery of Docetaxel: A Review. J Drug Deliv Ther. 2020 Oct;10(5-S):224-8.
22. Agrawal S, Garg A, Varshney V. Recent updates on applications of Lipid-based nanoparticles for site-specific drug delivery. Pharm Nanotechnol. 2022 Mar;10(1):24-41.
23. Gupta H, Srivastava AK. A Promising Approach for Improving Solubility and Bioavailability: Solid Lipid Nanoparticles. 2020 Jan;12(7):27-42.
24. Okur NÜ, Gökçe E. Lipid Nanoparticles for Ocular Drug Delivery. 2015 Dec;1(3):77-82.
25. Iqbal S, Ahmed H, Rafique F, Farooq M, Adnan S. Possibilities and challenges of next-generation therapeutics: solid lipid nanoparticles revolutionizing metabolic disorder treatment. J Diabetes Metab Disord. 2026 Jan.Vol.25(1):37.